RETRACTED: Downregulation of long non-coding RNA TUG1 suppresses tumor growth by promoting ubiquitination of MET in diffuse large B-cell lymphoma (Retracted Article)

被引:23
作者
Cheng, Hai [1 ]
Yan, Zhiling [1 ]
Wang, Xue [1 ]
Cao, Jiang [1 ]
Chen, Wei [1 ]
Qi, Kunming [1 ]
Zhou, Dian [1 ]
Xia, Jieyun [1 ]
Qi, Na [1 ]
Li, Zhenyu [1 ]
Xu, Kailin [1 ]
机构
[1] Xuzhou Med Univ, Affiliated Hosp, Key Lab Bone Marrow Stem Cell, Dept Hematol,Blood Dis Inst, 99 West Huaihai Rd, Xuzhou 221000, Jiangsu, Peoples R China
基金
中国国家自然科学基金;
关键词
Diffuse large B-cell lymphoma; Invasion; Long non-coding RNA; MET; TUG1; Ubiquitination; C-MET; RITUXIMAB; RECEPTOR; METASTASIS; EXPRESSION;
D O I
10.1007/s11010-019-03588-7
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Long non-coding RNAs (lncRNAs) can modulate gene expression through different mechanisms, but the fundamental molecular mechanism between lncRNAs and MET protein in diffuse large B-cell lymphoma (DLBCL) was poorly understood. The expression of lncRNA TUG1 and MET in DLBCL tissues and cell lines was determined by quantitative real-time PCR and western blotting. Cell proliferation, invasion and apoptosis were determined by cell counting kit-8 assay, transwell assay and flow cytometer. The animal xenograft model was established by the injection of DLBCL cells carrying si-TUG1. The expression of TUG1 and MET was upregulated in DLBCL tissues and cells. We demonstrated that MET was altered in the TUG1 knockdown DLBCL cells, and confirmed the interaction between TUG1 and MET by RNA pull-down and RNA immunoprecipitation. Furthermore, knockdown of TUG1 reduced MET protein level by promoting ubiquitination, and suppressed tumor growth in vitro and in vivo. Our findings demonstrated that TUG1 exerted its oncogenic function in DLBCL by inhibiting the ubiquitination and the subsequent degradation of MET. Knockdown of TUG1 through MET downregulation suppressed DLBCL cell proliferation and tumor growth.
引用
收藏
页码:47 / 56
页数:10
相关论文
共 32 条
  • [1] IDENTIFICATION OF THE HEPATOCYTE GROWTH-FACTOR RECEPTOR AS THE C-MET PROTOONCOGENE PRODUCT
    BOTTARO, DP
    RUBIN, JS
    FALETTO, DL
    CHAN, AML
    KMIECIK, TE
    VANDEWOUDE, GF
    AARONSON, SA
    [J]. SCIENCE, 1991, 251 (4995) : 802 - 804
  • [2] The long noncoding RNA TUG1 regulates blood-tumor barrier permeability by targeting miR-144
    Cai, Heng
    Xue, Yixue
    Wang, Ping
    Wang, Zhenhua
    Li, Zhen
    Hu, Yi
    Li, Zhiqing
    Shang, Xiuli
    Liu, Yunhui
    [J]. ONCOTARGET, 2015, 6 (23) : 19759 - 19779
  • [3] Long Noncoding RNAs, Chromatin, and Development
    Caley, Daniel P.
    Pink, Ryan C.
    Trujillano, Daniel
    Carter, David R. F.
    [J]. THESCIENTIFICWORLDJOURNAL, 2010, 10 : 90 - 102
  • [4] Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: An analysis of the Surveillance, Epidemiology and End Results database
    Castillo, Jorge J.
    Winer, Eric S.
    Olszewski, Adam J.
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (03) : 310 - 314
  • [5] Aberrant NEAT1_1 expression may be a predictive marker of poor prognosis in diffuse large B cell lymphoma
    Deng, Lan
    Jiang, Ling
    Tseng, Kuo-Fu
    Liu, Yuan
    Zhang, Xing
    Dong, Ruihong
    Lu, Zhigang
    Wang, Xiuju
    [J]. CANCER BIOMARKERS, 2018, 23 (02) : 157 - 164
  • [6] DIRENZO MF, 1992, ONCOGENE, V7, P2549
  • [7] Long non-coding RNAs expression levels in diffuse large B-cell lymphoma: An in silico analysis
    Dousti, Fatemeh
    Shahrisa, Arman
    Ansari, Hossein
    Hajjari, Mohammadreza
    Birgani, Yaser Tahmasebi
    Mohammadiasl, Javad
    Birgani, Maryam Tahmasebi
    [J]. PATHOLOGY RESEARCH AND PRACTICE, 2018, 214 (09) : 1462 - 1466
  • [8] Accumulation of miR-155 and BIC RNA in human B cell lymphomas
    Eis, PS
    Tam, W
    Sun, LP
    Chadburn, A
    Li, ZD
    Gomez, MF
    Lund, E
    Dahlberg, JE
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (10) : 3627 - 3632
  • [9] Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
    Green, Tina Marie
    Young, Ken H.
    Visco, Carlo
    Xu-Monette, Zijun Y.
    Orazi, Attilio
    Go, Ronald S.
    Nielsen, Ole
    Gadeberg, Ole V.
    Mourits-Andersen, Torben
    Frederiksen, Mikael
    Pedersen, Lars Moller
    Moller, Michael Boe
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (28) : 3460 - 3467
  • [10] HUMPHREY PA, 1995, AM J PATHOL, V147, P386